Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma

Christian Grommes, James L. Rubenstein, Lisa M. DeAngelis, Andres J.M. Ferreri, Tracy T. Batchelor

Research output: Contribution to journalArticlepeer-review

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma that affects the brain parenchyma, spinal cord, eyes, and cerebrospinal fluid without evidence of systemic, non-CNS involvement. PCNSL is uncommon and only a few randomized trials have been completed in the first-line setting. Over the past decades, the prognosis of PCNSL has improved, mainly due to the introduction and widespread use of high-dose methotrexate, which is now the backbone of all first-line treatment polychemotherapy regimens. Despite this progress, durable remission is recorded in only 50% of patients, and therapy can be associated with significant late neurotoxicity. Here, we overview the epidemiology, clinical presentation, staging evaluation, prognosis, and current up-to-date treatment of immunocompetent PCNSL patients.

Original languageEnglish
Pages (from-to)296-305
Number of pages10
JournalNeuro-Oncology
Volume21
Issue number3
DOIs
Publication statusPublished - Jan 1 2019

Keywords

  • Diagnosis
  • Methotrexate
  • PCNSL
  • Staging
  • Therapy

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma'. Together they form a unique fingerprint.

Cite this